Skip to main content
Erschienen in: Annals of Surgical Oncology 11/2009

01.11.2009 | Colorectal Cancer

Serum Carcinoembryonic Antigen Monitoring After Curative Resection for Colorectal Cancer: Clinical Significance of the Preoperative Level

verfasst von: In Ja Park, MD, Gyu-Seog Choi, MD, Kyoung Hoon Lim, MD, Byung Mo Kang, MD, Soo Han Jun, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 11/2009

Einloggen, um Zugang zu erhalten

Abstract

Aim

We evaluated preoperative serum carcinoembryonic antigen (CEA) as a prognostic factor for colorectal cancer and determined when surveillance of this marker was useful.

Methods

Serum CEA was measured preoperatively in 1,263 patients who underwent curative resection for colorectal cancer at 3-month intervals for the first 2 postoperative years and at 6-month intervals thereafter. Mean follow-up was 48 months (range 1–156 months).

Results

The 5-year disease-free survival was less in patients with a high preoperative serum CEA level (P < 0.0001). Among patients with a tumor recurrence, 38.5% had high follow-up serum CEA levels. The number of patients with high postoperative serum CEA levels exceeded the number of patients with high preoperative levels. High preoperative and follow-up serum CEA levels were independent prognostic factors for tumor recurrence (P = 0.003 and P < 0.001, respectively). In patients with high preoperative serum CEA levels, CEA surveillance had a 92.3% positive predictive value (PPV) and a 96.1% negative predictive value (NPV). The mean interval between postoperative serum CEA elevation and the diagnosis of a tumor recurrence [diagnostic interval (DI)] was 2.5 months (range 5–17 months). The DI was 0 in 18.8% of patients with a tumor recurrence.

Conclusion

High serum CEA levels preoperatively and at follow-up are prognostic factors for colorectal cancer. Postoperative serum CEA surveillance is used most effectively when patients have high preoperative serum CEA levels. Considering the DI of 0 in 18.8% of the patients, the current CEA surveillance schedule might be changed.
Literatur
1.
Zurück zum Zitat Chapman MA, Buckley D, Henson DB, Armitage NC. Preoperative carcinoembryonic antigen is related to tumour stage and long-term survival in colorectal cancer. Br J Cancer. 1998;78:1346–9.PubMed Chapman MA, Buckley D, Henson DB, Armitage NC. Preoperative carcinoembryonic antigen is related to tumour stage and long-term survival in colorectal cancer. Br J Cancer. 1998;78:1346–9.PubMed
2.
Zurück zum Zitat Morales-Gutierrez C, Vegh I, Colina F, Gomez-Camara A, Ignacio Landa J, Ballesteros D, et al. Survival of patients with colorectal carcinoma: possible prognostic value of tissular carbohydrate antigen 19.9 determination. Cancer. 1999;86:1675–81.CrossRefPubMed Morales-Gutierrez C, Vegh I, Colina F, Gomez-Camara A, Ignacio Landa J, Ballesteros D, et al. Survival of patients with colorectal carcinoma: possible prognostic value of tissular carbohydrate antigen 19.9 determination. Cancer. 1999;86:1675–81.CrossRefPubMed
3.
Zurück zum Zitat Reiter W, Stieber P, Reuter C, Nagel D, Lau-Werner U, Lamerz R. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer. Anticancer Res. 2000;20:5195–8.PubMed Reiter W, Stieber P, Reuter C, Nagel D, Lau-Werner U, Lamerz R. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer. Anticancer Res. 2000;20:5195–8.PubMed
4.
Zurück zum Zitat Stelzner S, Hellmich G, Koch R, Ludwig K. Factors predicting survival in stage IV colorectal carcinoma patients after palliative treatment: a multivariate analysis. J Surg Oncol. 2005;89:211–7.CrossRefPubMed Stelzner S, Hellmich G, Koch R, Ludwig K. Factors predicting survival in stage IV colorectal carcinoma patients after palliative treatment: a multivariate analysis. J Surg Oncol. 2005;89:211–7.CrossRefPubMed
5.
Zurück zum Zitat Takahashi Y, Mai M, Nakazato H. Preoperative CEA and PPD values as prognostic factors for immunochemotherapy using PSK and 5-FU. Anticancer Res. 2005;25:1377–84.PubMed Takahashi Y, Mai M, Nakazato H. Preoperative CEA and PPD values as prognostic factors for immunochemotherapy using PSK and 5-FU. Anticancer Res. 2005;25:1377–84.PubMed
6.
Zurück zum Zitat Chen CC, Yang SH, Lin JK, Lin TC, Chen WS, Jiang JK, et al. Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer? J Surg Res. 2005;124:169–74.CrossRefPubMed Chen CC, Yang SH, Lin JK, Lin TC, Chen WS, Jiang JK, et al. Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer? J Surg Res. 2005;124:169–74.CrossRefPubMed
7.
Zurück zum Zitat Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen C. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA. 1993;270:943–7.CrossRefPubMed Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen C. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA. 1993;270:943–7.CrossRefPubMed
8.
Zurück zum Zitat Wang JY, Tang R, Chiang JM. Value of carcinoembryonic antigen in the management of colorectal cancer. Dis Colon Rectum. 1994;37:272–7.CrossRefPubMed Wang JY, Tang R, Chiang JM. Value of carcinoembryonic antigen in the management of colorectal cancer. Dis Colon Rectum. 1994;37:272–7.CrossRefPubMed
9.
Zurück zum Zitat Wichmann MW, Lau-Werner U, Muller C, Hornung HM, Stieber P, Schildberg FW. Colorectal Cancer Study Group. Carcinoembryonic antigen for the detection of recurrent disease following curative resection of colorectal cancer. Anticancer Res. 2000;20:4953–5. Wichmann MW, Lau-Werner U, Muller C, Hornung HM, Stieber P, Schildberg FW. Colorectal Cancer Study Group. Carcinoembryonic antigen for the detection of recurrent disease following curative resection of colorectal cancer. Anticancer Res. 2000;20:4953–5.
10.
Zurück zum Zitat Zeng Z, Cohen AM, Urmacher C. Usefulness of carcinoembryonic antigen monitoring despite normal preoperative values in node-positive colon cancer patients. Dis Colon Rectum. 1993;36:1063–8.CrossRefPubMed Zeng Z, Cohen AM, Urmacher C. Usefulness of carcinoembryonic antigen monitoring despite normal preoperative values in node-positive colon cancer patients. Dis Colon Rectum. 1993;36:1063–8.CrossRefPubMed
11.
Zurück zum Zitat Barillari P, Ramacciato G, Manetti G, Bovino A, Sammartino P, Stipa V. Surveillance of colorectal cancer: effectiveness of early detection of intraluminal recurrences on prognosis and survival of patients treated for cure. Dis Colon Rectum. 1996;39:388–93.CrossRefPubMed Barillari P, Ramacciato G, Manetti G, Bovino A, Sammartino P, Stipa V. Surveillance of colorectal cancer: effectiveness of early detection of intraluminal recurrences on prognosis and survival of patients treated for cure. Dis Colon Rectum. 1996;39:388–93.CrossRefPubMed
12.
Zurück zum Zitat Rockall TA, McDonald PJ. Carcinoembryonic antigen: its value in the follow-up of patients with colorectal cancer. Int J Colorectal Dis. 1999;14:73–7.CrossRefPubMed Rockall TA, McDonald PJ. Carcinoembryonic antigen: its value in the follow-up of patients with colorectal cancer. Int J Colorectal Dis. 1999;14:73–7.CrossRefPubMed
13.
Zurück zum Zitat Mariani G, Carmellini M, Bonaguidi F, Benelli MA, Toni MG. Serum CEA monitoring in the follow-up of colorectal cancer patients with negative preoperative serum CEA. Eur J Cancer. 1980;16:1099–103.PubMed Mariani G, Carmellini M, Bonaguidi F, Benelli MA, Toni MG. Serum CEA monitoring in the follow-up of colorectal cancer patients with negative preoperative serum CEA. Eur J Cancer. 1980;16:1099–103.PubMed
14.
Zurück zum Zitat Kievit J, van de Velde CJ. Utility and cost of carcinoembryonic antigen monitoring in colon cancer follow-up evaluation. A Markov analysis. Cancer. 1990;65:2580–7.CrossRefPubMed Kievit J, van de Velde CJ. Utility and cost of carcinoembryonic antigen monitoring in colon cancer follow-up evaluation. A Markov analysis. Cancer. 1990;65:2580–7.CrossRefPubMed
15.
Zurück zum Zitat Flamini E, Mercatali L, Nanni O, Calistri D, Nunziatini R, Zoli W, et al. Free DNA and carcinoembryonic antigen serum levels: an important combination for diagnosis of colorectal cancer. Clin Cancer Res. 2006;12:6985–8.CrossRefPubMed Flamini E, Mercatali L, Nanni O, Calistri D, Nunziatini R, Zoli W, et al. Free DNA and carcinoembryonic antigen serum levels: an important combination for diagnosis of colorectal cancer. Clin Cancer Res. 2006;12:6985–8.CrossRefPubMed
16.
Zurück zum Zitat Park YJ, Park KJ, Park JG, Lee KU, Choe KJ, Kim JP. Prognostic factors in 2230 Korean colorectal cancer patients: Analysis of consecutively operated cases. World J Surg. 1999;23:721–6.CrossRefPubMed Park YJ, Park KJ, Park JG, Lee KU, Choe KJ, Kim JP. Prognostic factors in 2230 Korean colorectal cancer patients: Analysis of consecutively operated cases. World J Surg. 1999;23:721–6.CrossRefPubMed
17.
Zurück zum Zitat Duffy MJ, van Dalen A, Haglund C, Hansson L, Klapdor R, Lamerz R, et al. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer. 2003;39:718–27.CrossRefPubMed Duffy MJ, van Dalen A, Haglund C, Hansson L, Klapdor R, Lamerz R, et al. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer. 2003;39:718–27.CrossRefPubMed
18.
Zurück zum Zitat Louhimo J, Carpelan-Holmstrom M, Alfthan H, Stenman UH, Jarvinen HJ, Haglund C. Serum HCG beta, CA 72-4 and CEA are independent prognostic factors in colorectal cancer. Int J Cancer. 2002;101:545–8.CrossRefPubMed Louhimo J, Carpelan-Holmstrom M, Alfthan H, Stenman UH, Jarvinen HJ, Haglund C. Serum HCG beta, CA 72-4 and CEA are independent prognostic factors in colorectal cancer. Int J Cancer. 2002;101:545–8.CrossRefPubMed
19.
Zurück zum Zitat Lindmark G, Bergstrom R, Pahlman L, Glimelius B. The association of preoperative serum tumour markers with Dukes’ stage and survival in colorectal cancer. Br J Cancer. 1995;71:1090–4.PubMed Lindmark G, Bergstrom R, Pahlman L, Glimelius B. The association of preoperative serum tumour markers with Dukes’ stage and survival in colorectal cancer. Br J Cancer. 1995;71:1090–4.PubMed
20.
Zurück zum Zitat Carpelan-Holmstrom M, Haglund C, Lundin J, Jarvinen H, Roberts P. Pre-operative serum levels of CA 242 and CEA predict outcome in colorectal cancer. Eur J Cancer. 1996;32A:1156–61.CrossRefPubMed Carpelan-Holmstrom M, Haglund C, Lundin J, Jarvinen H, Roberts P. Pre-operative serum levels of CA 242 and CEA predict outcome in colorectal cancer. Eur J Cancer. 1996;32A:1156–61.CrossRefPubMed
21.
Zurück zum Zitat Forones NM, Tanaka M. CEA and CA 19-9 as prognostic indexes in colorectal cancer. Hepatogastroenterology. 1999;46:905–8.PubMed Forones NM, Tanaka M. CEA and CA 19-9 as prognostic indexes in colorectal cancer. Hepatogastroenterology. 1999;46:905–8.PubMed
22.
Zurück zum Zitat Ueno H, Mochizuki H, Hatsuse K, Hase K, Yamamoto T. Indicators for treatment strategies of colorectal liver metastases. Ann Surg. 2000;231:59–66.CrossRefPubMed Ueno H, Mochizuki H, Hatsuse K, Hase K, Yamamoto T. Indicators for treatment strategies of colorectal liver metastases. Ann Surg. 2000;231:59–66.CrossRefPubMed
23.
Zurück zum Zitat Sorbye H, Dahl O. Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to oxaliplatin combination chemotherapy: implications for tumor marker monitoring and guidelines. J Clin Oncol. 2003;21:4466–7.CrossRefPubMed Sorbye H, Dahl O. Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to oxaliplatin combination chemotherapy: implications for tumor marker monitoring and guidelines. J Clin Oncol. 2003;21:4466–7.CrossRefPubMed
24.
Zurück zum Zitat Staab HJ, Anderer FA, Stumpf E, Hornung A, Fischer R, Kieninger G. Eighty-four potential second-look operations based on sequential carcinoembryonic antigen determinations and clinical investigations in patients with recurrent gastrointestinal cancer. Am J Surg. 1985;149:198–204.CrossRefPubMed Staab HJ, Anderer FA, Stumpf E, Hornung A, Fischer R, Kieninger G. Eighty-four potential second-look operations based on sequential carcinoembryonic antigen determinations and clinical investigations in patients with recurrent gastrointestinal cancer. Am J Surg. 1985;149:198–204.CrossRefPubMed
25.
Zurück zum Zitat McCall JL, Black RB, Rich CA, Harvey JR, Baker RA, Watts JM, et al. The value of serum carcinoembryonic antigen in predicting recurrent disease following curative resection of colorectal cancer. Dis Colon Rectum. 1994;37:875–1.CrossRefPubMed McCall JL, Black RB, Rich CA, Harvey JR, Baker RA, Watts JM, et al. The value of serum carcinoembryonic antigen in predicting recurrent disease following curative resection of colorectal cancer. Dis Colon Rectum. 1994;37:875–1.CrossRefPubMed
26.
Zurück zum Zitat Martin EW, Minton JP, Carey LC. CEA-directed second-look surgery in the asymptomatic patient after primary resection of colorectal carcinoma. Ann Surg. 1983;202:310–7.CrossRef Martin EW, Minton JP, Carey LC. CEA-directed second-look surgery in the asymptomatic patient after primary resection of colorectal carcinoma. Ann Surg. 1983;202:310–7.CrossRef
27.
Zurück zum Zitat Allen-Mersh TG. Aspects of treatment. Serum CEA in the follow-up of colorectal carcinoma. Experience in a District General Hospital. Ann L Coll Surg Eng. 1984;66:751–5. Allen-Mersh TG. Aspects of treatment. Serum CEA in the follow-up of colorectal carcinoma. Experience in a District General Hospital. Ann L Coll Surg Eng. 1984;66:751–5.
28.
Zurück zum Zitat Chau I, Allen MJ, Cunningham D, Norman AR, Brown G, Ford HE, et al. The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapyfor colorectal cancer. J Clin Oncol. 2004;22:1420–9.CrossRefPubMed Chau I, Allen MJ, Cunningham D, Norman AR, Brown G, Ford HE, et al. The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapyfor colorectal cancer. J Clin Oncol. 2004;22:1420–9.CrossRefPubMed
29.
Zurück zum Zitat Borie F, Combescure C, Daurès JP, et al. Cost-effectiveness of two follow-up strategies for curative resection of colorectal cancer: comparative study using a Markov model. World J Surg. 2004;28:563–9.PubMed Borie F, Combescure C, Daurès JP, et al. Cost-effectiveness of two follow-up strategies for curative resection of colorectal cancer: comparative study using a Markov model. World J Surg. 2004;28:563–9.PubMed
30.
Zurück zum Zitat Borie F, Daures JP, Millat B, et al. Cost and effectiveness of follow-up examinations in patients with colorectal cancer resected for cure in a French population-based study. J Gastrointest Surg. 2004;8:552–8.CrossRefPubMed Borie F, Daures JP, Millat B, et al. Cost and effectiveness of follow-up examinations in patients with colorectal cancer resected for cure in a French population-based study. J Gastrointest Surg. 2004;8:552–8.CrossRefPubMed
31.
Zurück zum Zitat Sugarbaker, PH, Gianola FJ, Dwyer A. A simplified plan for follow up of patients with colon and rectal cancer supported by prospective studies of laboratory and radiologic test results. Surgery. 1987;102:79–87.PubMed Sugarbaker, PH, Gianola FJ, Dwyer A. A simplified plan for follow up of patients with colon and rectal cancer supported by prospective studies of laboratory and radiologic test results. Surgery. 1987;102:79–87.PubMed
32.
Zurück zum Zitat Makela JT, Laitinen SO, Kairaluoma MI. Five year followup after radical surgery for colorectal cancer—results of a prospective randomized trial. Arch Surg. 1995;130:1062–7.PubMed Makela JT, Laitinen SO, Kairaluoma MI. Five year followup after radical surgery for colorectal cancer—results of a prospective randomized trial. Arch Surg. 1995;130:1062–7.PubMed
Metadaten
Titel
Serum Carcinoembryonic Antigen Monitoring After Curative Resection for Colorectal Cancer: Clinical Significance of the Preoperative Level
verfasst von
In Ja Park, MD
Gyu-Seog Choi, MD
Kyoung Hoon Lim, MD
Byung Mo Kang, MD
Soo Han Jun, MD
Publikationsdatum
01.11.2009
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 11/2009
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-009-0625-z

Weitere Artikel der Ausgabe 11/2009

Annals of Surgical Oncology 11/2009 Zur Ausgabe

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.